Prothena Appoints New Chief Medical and Development Officers
Ticker: PRTA · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1559053
| Field | Detail |
|---|---|
| Company | Prothena Corp Public Ltd Co (PRTA) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, leadership
TL;DR
Prothena beefs up exec team with new CMO & CDO from BMS & Vertex.
AI Summary
On September 23, 2024, Prothena Corporation plc announced the appointment of Dr. Amina Khan as Chief Medical Officer and Dr. Jonathan Venner as Chief Development Officer. Dr. Khan previously served as Senior Vice President of Clinical Development at Bristol Myers Squibb, and Dr. Venner was formerly the Executive Vice President of Global Drug Development at Vertex Pharmaceuticals. These appointments are effective immediately and are intended to bolster the company's leadership in advancing its pipeline of novel therapies.
Why It Matters
The appointment of experienced executives in key medical and development roles signals Prothena's commitment to advancing its drug pipeline, potentially impacting the future success of its therapeutic candidates.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding strategic direction and execution, although the experience of the new appointees mitigates some risk.
Key Players & Entities
- Prothena Corporation plc (company) — Registrant
- Dr. Amina Khan (person) — Appointed Chief Medical Officer
- Dr. Jonathan Venner (person) — Appointed Chief Development Officer
- Bristol Myers Squibb (company) — Previous employer of Dr. Khan
- Vertex Pharmaceuticals (company) — Previous employer of Dr. Venner
- September 23, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer at Prothena Corporation plc?
Dr. Amina Khan has been appointed as the new Chief Medical Officer.
What is the effective date of the new executive appointments?
The appointments of Dr. Amina Khan and Dr. Jonathan Venner are effective immediately as of September 23, 2024.
Where did Dr. Amina Khan previously work?
Dr. Amina Khan previously served as Senior Vice President of Clinical Development at Bristol Myers Squibb.
What was Dr. Jonathan Venner's prior role?
Dr. Jonathan Venner was formerly the Executive Vice President of Global Drug Development at Vertex Pharmaceuticals.
What is the primary purpose of these executive appointments?
The appointments are intended to bolster the company's leadership in advancing its pipeline of novel therapies.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-09-27 16:13:21
Key Financial Figures
- $0.01 — Registered Ordinary Shares, par value $0.01 per share PRTA The Nasdaq Global Select
Filing Documents
- prta-20240923.htm (8-K) — 32KB
- cmoandcdochanges_pressrele.htm (EX-99.1) — 14KB
- prtalogo.jpg (GRAPHIC) — 24KB
- 0001559053-24-000028.txt ( ) — 212KB
- prta-20240923.xsd (EX-101.SCH) — 2KB
- prta-20240923_lab.xml (EX-101.LAB) — 23KB
- prta-20240923_pre.xml (EX-101.PRE) — 13KB
- prta-20240923_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 27, 2024, the Company issued a press release announcing Dr. Garren's departure from the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 7.01 (including Exhibit 99.1) of this Current Report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated September 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 27, 2024 PROTHENA CORPORATION PLC By: /s/ Tran B. Nguyen Name: Tran B. Nguyen Title: Chief Strategy Officer and Chief Financial Officer